H. Lundbeck A/S's Brintellix® (Vortioxetine) For The Treatment Of Major Depressive Disorder In Adults Is Now Available In U.S. Pharmacies

Valby, Denmark and Osaka, Japan, 2014-01-21 15:00 CET (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceuticals Company Limited (Takeda) jointly announced today that Brintellix (vortioxetine), for the treatment of major depressive disorder (MDD) in adults, is available in pharmacies across the United States (U.S.) – following initial availability through wholesalers soon after its September 30 approval by the U.S. Food and Drug Administration. Brintellix is a once-daily oral antidepressant available in a range of doses, to help address the variability of patient needs.

Help employers find you! Check out all the jobs and post your resume.